Mister Car Wash "announced that it has entered into a definitive agreement to acquire Clean Streak Ventures LLC, a portfolio company of MKH Capital Partners. The acquisition of Clean Streak includes 23 operating locations, 10 development locations and the underlying real estate at all 33 locations. The development locations are in various stages of the permitting and construction cycle and are expected to open within the next year under the Mister Car Wash brand. In addition, the Company plans to rebrand and integrate the 23 existing operating locations that are currently doing business under the tradenames Top Dog Express and Clean Machine Car Wash into the Mister Car Wash brand. The acquisition will expand the Company's footprint in Florida and provide even more options for customers to access Mister's services throughout the state. The addition of these locations will bring the Company's total operating stores in Florida to 65, with new market entry into 5 MSAs including Cape Coral/ Ft. Myers and Miami. The expansion is also expected to enable the Company to leverage efficiencies across its existing regional infrastructure."

The company states: "The New Mexico Public Regulation Commission, or NMPRC, rejected the agreement reached by parties in the merger application involving PNM Resources (PNM), its wholly-owned subsidiary Public Service Company of New Mexico, and AVANGRID (AGR). The NMPRC voted 5-0 to reject the parties' agreements reached in the merger proceedings, following a 4-1 vote to deny a request for oral argument seeking to address concerns expressed by the NMPRC. Five federal agencies and the Public Utilities Commission of Texas had already completed their reviews and approved the proposed merger, leaving the New Mexico Public Regulation Commission as the only remaining approval necessary for the merger. The original application before the NMPRC was filed in November 2020."

Great Bear Resources (GTBAF) announced that it has entered into a binding agreement with Kinross Gold (KGC) under which Kinross has agreed to acquire all of the outstanding common shares of Great Bear. Under the terms of the Transaction, Great Bear shareholders will receive upfront consideration of approximately C$1.8B, representing C$29.00 per Great Bear common share on a fully diluted basis. Great Bear shareholders will be able to elect to receive the upfront consideration as either (i) C$29.00 in cash or (ii) 3.8564 Kinross shares per Great Bear share, both subject to proration. The upfront consideration will be subject to maximum aggregate cash consideration of approximately C$1.4B or maximum aggregate shares issuable of 95.8M, depending on the election of Great Bear shareholders.

The dividend will be paid on January 7, 2022, to shareholders of record as of the close of business on December 23, 2021.

In a regulatory filing, Shyft Group director Ronald Edward Harbour disclosed the sale of 20,000 common shares of the company on December 7 at a price of $49.3977 per share.

Alerus Financial announced the signing of a definitive agreement and plan of merger to acquire MPB BHC, the bank holding company for Metro Phoenix Bank, the largest full-service community bank headquartered in Phoenix. The transaction represents the twenty-fifth acquisition for Alerus since 2000. The acquisition significantly increases the Alerus presence in Arizona and, following the completion of the transaction, Alerus will have the fifth largest deposit market share in the Phoenix metropolitan statistical area among community banks. On a pro forma basis, Alerus will operate three branch locations in Arizona. The combined company's Arizona operation will have approximately $439M in total loans and approximately $483M in total deposits. Alerus Chief Financial Officer Katie Lorenson, who will succeed Randy Newman as Alerus President and Chief Executive Officer on January 1, 2022, led the negotiations for the acquisition. Upon completion of the transaction, Haggard will join Alerus as President of its Arizona Market, ensuring a smooth transition for clients and employees. In this role, he will also be a member of Alerus' leadership team and oversee growth for the company in the Arizona market. Subject to the terms of the agreement and plan of merger, MPHX shareholders will receive 0.74 Alerus common shares for each outstanding MPHX share, or approximately 2.58M Alerus shares in the aggregate. Using a price per share of Alerus common stock of $31.43 as of December 7, 2021, the transaction has an implied purchase price of $23.26 per share, which equates to an aggregate value of $85.3M, including $4.3M in consideration for option holders. The transaction is anticipated to be immediately accretive to Alerus' earnings per share, excluding one-time transaction related expenses, and approximately 8.5% accretive in the first full year. The agreement and plan of merger has been approved by the boards of directors of Alerus and MPHX. Completion of the merger is subject to customary closing conditions, including receipt of required regulatory approvals and the approval by the shareholders of MPHX. The transaction is expected to close in the first quarter of 2022, and the data processing system conversion will occur in the first half of 2022 subsequent to the closing. Alerus currently intends to merge Metro Phoenix Bank into Alerus Financial, N.A. at that time.

In a regulatory filing, Tetra Tech chairman and CEO Dan Batrack disclosed the sale of 64,000 common shares of the company on December 6 at a price of $185.7483 per share.

Enfusion announced the opening of a new office in Sydney, Australia, which will be Enfusion's first in Oceania. The location in Sydney will allow Enfusion to adequately respond to the increased demand for innovative operational solutions and extend its best-in-class SaaS platform and technology-enabled services to a growing base of investment managers in the region. "We doubled down in several regions including Asia, Europe, the Middle East and Africa, and North America over the past year, and due to the increasing demand for our solutions in Australia and New Zealand, we knew the best next step was to solidify our presence in Sydney, which also allows us to better serve our existing clients," said Thomas Kim, CEO of Enfusion. "Sydney will be our tenth global office as we continue to make our cloud-native SaaS platform and managed services solutions available globally, while catering to the unique needs for each market. We are thrilled to better support our existing clients in the region and look forward to the opportunities ahead."

Valaris announced that its Board of Directors has appointed Anton Dibowitz as President and CEO, effective immediately. Dibowitz, who has been serving as interim President and CEO of Valaris since September 3, is also a member of the company's Board of Directors. Prior to joining the Board, Dibowitz served as an advisor of Seadrill Ltd. from November 2020 until March 2021, and as Seadrill's CEO from July 2017 until October 2020.

IBEX Limited announces that its board of directors has authorized the repurchase of up to $20M of the company's common stock.

Zymeworks announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer. The data are being presented at the San Antonio Breast Cancer Symposium taking place December 7-10. In addition, Zymeworks will present a Trial in Progress poster detailing the ongoing clinical trial evaluating zanidatamab in combination with the CD47-blocker, evorpacept. The data presented at SABCS are from a clinical study of 24 patients with heavily pretreated HER2-positive metastatic breast cancer who received zanidatamab in combination with either vinorelbine - n=12 -, capecitabine - n=8 -, or paclitaxel - n=4 -. In 22 efficacy-evaluable patients, treatment with zanidatamab and chemotherapy resulted in a cORR of 36.4% and DCR of 86.4%, and the majority of patients experienced a decrease in their tumor size. The mPFS is 7.3 months across all treatment regimens with 42% of patients still on study at the time of data cutoff. Zanidatamab in combination with single agent chemotherapy is well tolerated, with the majority of treatment-related adverse events considered mild to moderate in severity. Zanidatamab is also being evaluated in several Phase 2 clinical trials for HER2 expressing gastroesophageal, colorectal, and breast cancers. The FDA has granted zanidatamab with Breakthrough Therapy designation as well as two Fast Track designations. These designations mean zanidatamab is eligible for Accelerated Approval, Priority Review and Rolling Review. Zanidatamab has also received Orphan Drug designations from the FDA as well as the European Medicines Agency for the treatment of biliary tract and gastric cancers.